FDA Approves Omeros’ YARTEMLEA® – First and Only Therapy Indicated for TA-TMA
Approval of YARTEMLEA was based on results from a single-arm, open-label study in adults with TA-TMA (the TA-TMA…
Ocular manifestations of primary thrombotic microangiopathies : a descriptive systematic review | BMC Ophthalmology
Tsai H-M. Untying the knot of thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome. Am J Med. 2013,…